Samsung Electronics Invests in Samsung Biologics Rights Offering
Article excerpt
Highlighted: the sentence this signal was extracted from
Samsung Electronics will participate in a paid-in capital increase by Samsung Biologics, investing 666.2 billion won (about $500 million). Samsung Electronics disclosed on Oct. 29 that it held a board of directors meeting and resolved the agenda to acquire 567,503 common shares of Samsung Biologics. This investment represents participation as an existing shareholder in a paid-in capital increase of approximately 3 trillion won pursued by Samsung Biologics. As of the end of the first half of this year, Samsung Electronics is the second-largest shareholder, holding a 31.22% stake in Samsung Biologics. Samsung Electronics will subscribe to the entire volume (100%) of its allocated new shares. The scheduled payment date for the shares is on Nov. 17. Samsung C&T, the largest shareholder with a 43.06% stake, also decided to invest 919 billion won to purchase 782,818 shares of Samsung Biologics. However, the investment amount was calculated based on the issue price per share of the new shares for the paid-in capital increase, which Samsung Biologics disclosed on Oct. 1. The amount is subject to change depending on the final issue price, which will be determined on Nov. 5.